A narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes

References

• World Health OrganizationGlobal summary of the HIV/AIDS epidemic: 2013–2014 Available from: http://www.who.int/hiv/data/epi_core_dec2014.png?ua=1Accessed February 25, 2015
   Google Scholar
• MontanerJGReissPCooperDA randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. Italy, The Netherlands, Canada and Australia StudyJAMA1998279129309379544767
   PubMed Web of Science ®Google Scholar
• CardosoSWTorresTSSantini-OliveiraMMarinsLMVelosoVGGrinsztejnBAging with HIV: a practical reviewBraz J Infect Dis201317446447923711587
   PubMed Web of Science ®Google Scholar
• MontanerJSHoggRWoodEThe case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemicLancet2006368953453153616890841
   PubMed Web of Science ®Google Scholar
• MoeremansKHemmettLHjelmgrenJCost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UKPharmacoeconomics201028114716721182349
   PubMed Web of Science ®Google Scholar
• LongEFBrandeauMLGalvinCMEffectiveness and cost- effectiveness of strategies to expand antiretroviral therapy in St Petersburg, RussiaAIDS200620172207221517086061
   PubMed Web of Science ®Google Scholar
• VijayaraghavanAEfrusyMBMazonsonPDEbrahimOSanneIMSantasCCCost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing worldJ Acquir Immune Defic Syndr20074619110017621241
   PubMed Web of Science ®Google Scholar
• HubbenGABosJMVeltman-StarkenburgCACost- effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the NetherlandsCost Eff Resour Alloc200751518034881
   PubMedGoogle Scholar
• JohnstonKMLevyARLimaVDExpanding access to HAART: a cost-effective approach for treating and preventing HIVAIDS201024121929193520588171
   PubMed Web of Science ®Google Scholar
• BinagwahoAPegurriEDrobacPCPrevention of mother-to-child transmission of HIV: cost-effectiveness of antiretroviral regimens and feeding options in RwandaPLoS One201382e5418023437040
   PubMed Web of Science ®Google Scholar
• OrlandoSMarazziMCMancinelliSCost-effectiveness of using HAART in prevention of mother-to-child transmission in the DREAM-project MalawiJ Acquir Immune Defic Syndr201055563163421934555
   PubMed Web of Science ®Google Scholar
• BroganAMauskopfJTalbirdSESmetsEUS cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN trialPharmacoeconomics201028Suppl 112914621182348
   PubMed Web of Science ®Google Scholar
• SimpsonKNRobertsGHicksCBFinnernHWCost-effectiveness of tipranavir in treatment-experienced HIV patients in the United StatesHIV Clin Trials20089422523718753117
   PubMed Web of Science ®Google Scholar
• BadriMMaartensGMandaliaSCost-effectiveness of highly active antiretroviral therapy in South AfricaPLoS Med200631e416318413
   PubMed Web of Science ®Google Scholar
• MarseilleEKahnJGPitterCThe cost effectiveness of home-based provision of antiretroviral therapy in rural UgandaAppl Health Econ Health Policy20097422924319905037
   PubMedGoogle Scholar
• RizzardiniGBonfantiPCarenziLCost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern ItalyTher Clin Risk Manag2012837738423028230
   PubMed Web of Science ®Google Scholar
• ColomboGLDi MatteoSAntinoriAMedagliaMMurachelliSRizzardiniGEconomic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelinesClinicoecon Outcomes Res2013548949624124383
   PubMedGoogle Scholar
• McCabeCJGoldieSJFismanDNThe cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant womenPLoS One201054e1015420405011
   PubMed Web of Science ®Google Scholar
• MunakataJBennerJSBeckerSDeziiCMHazardEHTierceJCClinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virusMed Care2006441089389917001259
   PubMed Web of Science ®Google Scholar
• ColomboGLColangeliVDi BiagioADi MatteoSViscoliCVialePCost-effectiveness analysis of initial HIV treatment under Italian guidelinesClinicoecon Outcomes Res2011319720522163167
   PubMedGoogle Scholar
• GranichRKahnJGBennettRExpanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011–2050PLoS One201272e3021622348000
   PubMed Web of Science ®Google Scholar
• FangCTChangYYHsuHMCost-effectiveness of highly active antiretroviral therapy for HIV infection in TaiwanJ Formos Med Assoc2007106863164017711796
   PubMed Web of Science ®Google Scholar
• OnoSKurotakiTNakasoneTCost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in ThailandJpn J Infect Dis200659316817316785697
   PubMed Web of Science ®Google Scholar
• BadriMClearySMaartensGWhen to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness studyAntivir Ther2006111637216518961
   PubMed Web of Science ®Google Scholar
• MauskopfJKitahataMKaufTRichterATolsonJHIV antiretroviral treatment: early versus laterJ Acquir Immune Defic Syndr200539556256916044008
   PubMed Web of Science ®Google Scholar
• MauskopfJBroganAMartinSSmetsECost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USAPharmacoeconomics201028Suppl 18310521182346
   PubMed Web of Science ®Google Scholar
• HarrisMNosykBHarriganRLimaVDCohenCMontanerJCost-effectiveness of antiretroviral therapy for multidrug-resistant HIV: past, present, and futureAIDS Res Treat2012201259576223193464
   PubMedGoogle Scholar